Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

MAGA and MAHA are happily married in Florida, and nowhere more at home than in Sarasota County, where on a humid October night a crowd of several hundred gathered to ...

Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and gro ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech / pharma companiesAddressing large and ...

Even so, Berkley gives Trump credit for Operation Warp Speed. White House spokesperson Kush Desai said in response: “President Trump’s Operation Warp Speed was a bold and innovative public-private ...

Reports Q3 revenue EUR 1.52B vs. EUR 1.24B last year. “In the third quarter, we made substantial progress in executing against our oncology ...

Among other things, the focus is on a drug candidate called Pumitamig, formerly BNT327, and mRNA-based immunotherapies and antibody ... Chief executive Ugur Sahin said that decisive progress has been ...

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025), was held from June 15–19, 2025, in Bruges, Belgium. This “Column Watch” installment ...